Günter Weiss - Infectious Diseases

Author Information

Günter Weiss is a distinguished researcher affiliated with the Department of Internal Medicine II, specializing in Infectious Diseases, Pneumology, and Rheumatology at the Medical University Innsbruck, located in Innsbruck, Austria. His work primarily focuses on infectious diseases, with a significant interest in COVID-19, as evidenced by his recent publications. Dr. Weiss's research is critical in understanding the clinical and proteomic aspects of infectious diseases, particularly in the context of the ongoing pandemic.

Research Contributions

Günter Weiss has made substantial contributions to the field of infectious diseases through his extensive research on COVID-19. His work includes the development and clinical application of biomarkers for early COVID-19 detection, evaluation of mental health risks following COVID-19 outpatient management, and studies on antibody levels against the SARS-CoV-2 spike protein. Additionally, Dr. Weiss has been involved in projects that predict the mortality of hospitalized COVID-19 patients and identify symptoms that may indicate long COVID. His research is pivotal in improving the clinical management and understanding of COVID-19 and its long-term effects.

Aliases

Günter Weiss is also known by the aliases G Weiss and G. Weiss. These variations are commonly used in his publications and citations.

Publication and Citation Metrics

Metric	Value
Total Papers	34
Total Citations	359
H-index	8

Publications:

Who Is at Risk of Poor Mental Health Following Coronavirus Disease-19 Outpatient Management?

DOI: 10.3389/fmed.2022.792881

Year: 2022

Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study

DOI: 10.1101/2022.01.20.22269599

Year: 2022

Predictive Performance and Clinical Application of COV50, A Urinary Proteomic Biomarker in Early COVID-19 Infection: A Cohort Study

DOI: 10.2139/ssrn.4006139

Year: 2022

Clinical validation of the quantitative Siemens SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

DOI: 10.1101/2021.02.17.21251907

Year: 2021

A proteomic survival predictor for COVID-19 patients in intensive care

DOI: 10.1101/2021.06.24.21259374

Year: 2021

A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation

DOI: 10.3389/fcimb.2021.795026

Year: 2021

Coronavirus Disease 2019: Clinics, Treatment, and Prevention

DOI: 10.3389/fmicb.2021.761887

Year: 2021

Who is at risk of poor mental health following COVID-19 outpatient management?

DOI: 10.1101/2021.09.22.21263949

Year: 2021

Late Breaking Abstract - Acute multi-organ symptoms predict long COVID

DOI: 10.1183/13993003.congress-2021.pa453

Year: 2021

Borderline and weakly positive antibody levels against the S-protein of SARS-CoV-2 exhibit limited agreement with virus neutralization titres

DOI: 10.1016/j.jcvp.2021.100058

Year: 2021

How Does Genomics Aid in Identifying Pathogens?

What is Genomics?

What is the Role of Genomics in Tracking Disease Outbreaks?

How Can Genomics Improve Diagnostics?

What are Viruses?

What are the Implications of Genomics for Treatment?

How is Cervical Cancer Linked to Infectious Diseases?

What Are the Treatment Options for Infected Newborns?

How Does Genomics Contribute to Vaccine Development?

How are Protein Targets Identified?

Partnered Content Networks

Relevant Topics